|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
treatment of certain cancers
treatment of severe allergies
treatment of autoimmune diseases
treatment of COVID-19 (severe cases)
treatment of inflammatory conditions
|
|
gptkbp:ATCCode
|
gptkb:H02AB02
|
|
gptkbp:CASNumber
|
gptkb:50-02-2
|
|
gptkbp:commonName
|
gptkb:Dexamethasone
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:discoveredBy
|
1957
|
|
gptkbp:eliminationHalfLife
|
36-54 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:has_solubility_in_ethanol
|
soluble
|
|
gptkbp:hasInChIKey
|
WB9WQNOYRKHKKW-RUDMXATFSA-N
|
|
gptkbp:hasMolecularFormula
|
C22H29FO5
|
|
gptkbp:hasSMILES
|
gptkb:C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)O
|
|
gptkbp:hasUNII
|
7S5I7G3JQL
|
|
gptkbp:heldBy
|
gptkb:Corticosteroid
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
50-02-2
|
|
gptkbp:isOn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:IUPACName
|
gptkb:(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:meltingPoint
|
262-264 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
392.461 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL384
gptkb:DB01234
5743
5542
|
|
gptkbp:routeOfAdministration
|
oral
topical
intramuscular
inhalation
intravenous
ophthalmic
|
|
gptkbp:sideEffect
|
gptkb:cataracts
gptkb:bone
immunosuppression
hypertension
glaucoma
mood changes
weight gain
insomnia
hyperglycemia
|
|
gptkbp:solubility
|
practically insoluble
|
|
gptkbp:usedFor
|
anti-inflammatory agent
immunosuppressant
|
|
gptkbp:bfsParent
|
gptkb:dexamethasone
|
|
gptkbp:bfsLayer
|
5
|